Navigation Links
Inverness Medical Innovations, Inc. Announces Offering of $150 Million of Senior Notes
Date:8/4/2009

WALTHAM, Mass., Aug. 4 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (NYSE: IMA), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, today announced that it intends to offer $150 million of senior notes due 2016 in a public offering. Payment of the notes will be guaranteed by certain of Inverness' domestic subsidiaries. Inverness intends to use the net proceeds from the offering solely to fund its previously announced acquisition of Concateno plc, which the Company expects to close on or about August 11, 2009.

Jefferies & Company, Inc., Goldman, Sachs & Co. and Well Fargo Securities, LLC will act as joint book-running managers for the offering.

The offering will be made under Inverness' shelf registration statement on Form S-3 filed with the SEC on April 10, 2009 and amended on August 4, 2009. Inverness intends to file with the SEC later today a preliminary prospectus supplement and accompanying prospectus for the offering to which this communication relates. Before you invest, you should read the preliminary prospectus supplement, the accompanying prospectus, and the other documents we have filed with the SEC for more complete information about us and the offering. You may obtain these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, a copy of the preliminary prospectus supplement and accompanying prospectus may be obtained from Jefferies & Company, Inc. at One Station Place, Three North, Stamford, CT 06902, Attention: Timothy Lepore or at 1-888-708-5831, from Goldman, Sachs & Co. at 85 Broad Street, New York, NY 10004, Attention: Prospectus Department, or at 1-866-471-2526, or Wells Fargo Securities, LLC at 301 South College Street, Sixth Floor, Charlotte, NC 28202, Attention: High Yield Syndicate or at 1-704-715-8324.

This press release is neither an offer to sell nor a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Inverness

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life at home. Inverness' global leading products and services, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the expected offering and the use of proceeds. These statements reflect Inverness' current views with respect to future events and are based on management's current assumptions and information currently available. Actual results may differ materially due to numerous factors including, without limitation, risks associated with market and economic conditions. Inverness undertakes no obligation to update any forward-looking statements contained herein.


'/>"/>
SOURCE Inverness Medical Innovations, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CVS Caremark and Inverness Medical Innovations Launch Strategic Alliance to Provide Enhanced Health Management Services to Clients
2. Inverness Medical Innovations Announces Second Quarter 2009 Results
3. Inverness Medical Innovations Proposes to Acquire Concateno plc
4. Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
5. Inverness Medical Innovations to Present at the Deutsche Bank 34th Annual Health Care Conference on May 19, 2009
6. Inverness Medical Innovations to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference on May 12, 2009
7. Inverness Medical Innovations, Inc. Announces Offering of $200 Million of Senior Subordinated Notes
8. Inverness Medical Innovations Announces First Quarter 2009 Results
9. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET April 27, 2009 to Discuss First Quarter 2009 Results
10. Inverness Medical Innovations to Participate at Goldman Sachs Leveraged Finance Healthcare Conference on April 8, 2009
11. Eli Y. Adashi, MD, MS, FACOG, Joins Inverness Medical Innovations Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... 30, 2017 , ... The Aresty Institute of Executive Education ... to address the increasingly complex educational needs of today's global executives. Corporate ... corporate finance and will increase their ability to confidently take action in ways ...
(Date:3/30/2017)... ... 30, 2017 , ... Nutrition Education for the Public (NEP), ... join nonprofit Seafood Nutrition Partnership (SNP) in presenting “Eating Heart Healthy: Exploring Issues ... educators and students inform consumers about the health benefits of eating a seafood-rich ...
(Date:3/29/2017)... ... , ... During the last week of March, Chad Kawa, MD of Revere ... the local community. , Colon cancer is the second leading cause of cancer ... it is small, confined and easier to treat. If you are 50 or older, ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... women’s professional squash, announced it has enlisted New York City-based sports and entertainment ... will develop and procure sponsorship opportunities for the Professional Squash Association (PSA), which ...
(Date:3/29/2017)... Baltimore, MD (PRWEB) , ... March 30, 2017 , ... ... , Charm City Run has announced that Mercy Medical Center will serve as the ... in the Mid-Atlantic region. On Sunday, June 25, 2017, thousands of women will walk ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Research and Markets has announced the ... 2025" report to their offering. ... The global orthopedic navigation ... 2025. Increasing geriatric population prone to orthopedic diseases is a ... over the forecast period. Osteoarthritis and osteoporosis are most common ...
(Date:3/29/2017)... , March 29, 2017  Experts in the ... monitoring devices like  Soberlink Systems  as a model ... paper, published in early 2017, concluded that remote ... in managing patient recovery." The findings ... of Addiction Medicine, detail a range of variables ...
(Date:3/29/2017)... , March 29, 2017  Glenmark Pharmaceuticals, a ... GSP 301, an investigational fixed-dose combination of mometasone ... administered twice-daily as a nasal spray being studied ... results are from a recently completed Phase 3 ... 301 combination therapy versus mometasone, olopatadine or placebo. ...
Breaking Medicine Technology: